{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:33:39Z","timestamp":1746711219061,"version":"3.40.5"},"reference-count":13,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:title>This Policy Statement was retired January 2015.<\/jats:title>\n               <jats:p>The American Academy of Pediatrics and the Centers for Disease Control and Prevention are amending previous recommendations and making additional recommendations for the use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap). Review of the results from clinical trials and other studies has revealed no excess reactogenicity when Tdap is given within a short interval after other tetanus- or diphtheria-containing toxoid products, and accrual of postmarketing adverse-events reports reveals an excellent safety record for Tdap. Thus, the recommendation for caution regarding Tdap use within any interval after a tetanus- or diphtheria-containing toxoid product is removed. Tdap should be given when it is indicated and when no contraindication exists. In further efforts to protect people who are susceptible to pertussis, the American Academy of Pediatrics and Centers for Disease Control and Prevention recommend a single dose of Tdap for children 7 through 10 years of age who were underimmunized with diphtheria-tetanus-acellular pertussis (DTaP). Also, the age for recommendation for Tdap is extended to those aged 65 years and older who have or are likely to have contact with an infant younger than 12 months (eg, health care personnel, grandparents, and other caregivers).<\/jats:p>","DOI":"10.1542\/peds.2011-1752","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T03:44:22Z","timestamp":1317095062000},"page":"809-812","source":"Crossref","is-referenced-by-count":12,"title":["Additional Recommendations for Use of Tetanus Toxoid, Reduced-Content Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap)"],"prefix":"10.1542","volume":"128","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"issue":"3","key":"2023092514505649700_B1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1542\/peds.2005-3038","article-title":"Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine","volume":"117","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2006","journal-title":"Pediatrics"},{"issue":"RR-17","key":"2023092514505649700_B2","first-page":"1","article-title":"Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel","volume":"55","author":"Kretsinger","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"2023092514505649700_B3","first-page":"13","article-title":"Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morbid Mortal Wkly Rep"},{"key":"2023092514505649700_B4","first-page":"504","article-title":"Pertussis","volume-title":"Red Book: 2009 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2009","edition":"28th ed"},{"issue":"RR-4","key":"2023092514505649700_B5","first-page":"1","article-title":"Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Murphy","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"2023092514505649700_B6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.inf.0000202082.56403.c4","article-title":"How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?","volume":"25","author":"Halperin","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"2023092514505649700_B7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4161\/hv.5.5.6911","article-title":"Safety of Tdap-IPV given 1 month after Td-IPV booster in healthy young adults: a placebo controlled trial","volume":"5","author":"Beytout","year":"2009","journal-title":"Hum Vaccin"},{"issue":"50","key":"2023092514505649700_B8","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1016\/j.vaccine.2010.09.034","article-title":"The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak","volume":"28","author":"Talbot","year":"2010","journal-title":"Vaccine"},{"issue":"36","key":"2023092514505649700_B9","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1016\/j.vaccine.2009.06.038","article-title":"Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study","volume":"27","author":"Jackson","year":"2009","journal-title":"Vaccine"},{"issue":"32","key":"2023092514505649700_B10","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1016\/j.vaccine.2009.05.036","article-title":"An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink","volume":"27","author":"Yih","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"2023092514505649700_B11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.vaccine.2006.09.053","article-title":"An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4\u20136 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine","volume":"25","author":"Langley","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"2023092514505649700_B12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4161\/hv.4.3.5290","article-title":"Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation","volume":"4","author":"Meyer","year":"2008","journal-title":"Hum Vaccin"},{"issue":"12","key":"2023092514505649700_B13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/01.inf.0000190028.96152.46","article-title":"A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial","volume":"24","author":"Scheifele","year":"2005","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/4\/809\/1531501\/zpe01011000809.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/4\/809\/1531501\/zpe01011000809.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:52:20Z","timestamp":1695653540000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/128\/4\/809\/30700\/Additional-Recommendations-for-Use-of-Tetanus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,10,1]]},"published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2011-1752","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}